Click and listen to Professor John Gribben, Barts Cancer Institute, talk about Replase treatment. He talks about the novel agents targeting the B-cell receptor pathway, and how BLC2 inhibitors have now replaced chemoimmunotherapy for relapsed CLL. Agents inhibiting these pathways have unprecedented activity in CLL, especially in high risk patients who previously had such a poor prognosis.
If you are a doctor, nurse, pharmacist or other healthcare professional with the right to prescribe medicine, you can:
Already a member?
Log in
| Cookie | Duration | Description |
|---|---|---|
| _ga | 2 years | This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors. |
| _gid | 1 day | This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form. |
| Cookie | Duration | Description |
|---|---|---|
| _gat_UA-43794127-5 | 1 minute | This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites. |
